14016-71-8Relevant academic research and scientific papers
BCL6 INHIBITORS AS ANTICANCER AGENTS
-
Page/Page column 34; 39, (2015/01/07)
The invention provides compositions and methods for blocking the BCL6 BTB domain with small molecule, non-peptide compounds as disclosed and claimed herein. BCL6 is a transcriptional repressor of the BTB-POZ (bric a brac, tramtrack, broad complex / pox virus zinc finger) family of proteins. It is required for normal development of germinal center (GC) B-cells and is also the most commonly involved oncogene in diffuse large B-cell lymphomas (DLBCLs), and constitutive expression of BCL6 in GC B-cells causes DLBCL in mice. DLBCLs are aggressive tumors that arise from germinal center (GC) B- cells and are the most common form of non-Hodgkin's lymphomas. BCL6 is required for survival of DLBCL cells and can limit their ability to respond to DNA damaging agents. It is also frequently expressed in follicular lymphomas (FLs), and may be required for survival of these tumors as well. DLBCL and FL collectively constitute ～60-70% of B-cell lymphomas and the incidence of these tumors has been rising in recent decades.
Room temperature catalyst-free Knoevenagel condensation: Facile access to isatinylidenerhodanines
Xue, Fengtian,MacKerell Jr., Alexander D.,Heinzl, Geoffrey,Hom, Kellie
supporting information, p. 1700 - 1703 (2013/04/10)
A catalyst-free Knoevenagel type synthesis of isatinylidenerhodanines is reported starting from substituted isatins and rhodanines. The reaction proceeds spontaneously at room temperature in dimethyl sulfoxide (DMSO), employing a unique macrocyclic intermediate formed through an intramolecular H-bonding. Various substituted isatinylidenerhodanines could be synthesized in good yields.
